Following as we in CT are updating processes as well.

Thank you.

 

Regina Ali, BSN, RN, BC 

Colleague Health Nurse Manager  

Central Region

Hartford HealthCare

Colleague Health Services

100 Grand Street, New Britain, CT 06050
435 Lewis Ave, Meriden, CT 06450

P: 860-224-5605

C: 203-687-8527

F: 860-224-5745

E: regina.ali@hhchealth.org

 

 

This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. DO NOT FORWARD THIS E-MAIL. Any unauthorized review, use, disclosure, or distribution is prohibited. If you are not the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message, including any attachments.

 

From: MCOH-EH <mcoh-eh-bounces@mylist.net> On Behalf Of David S. Cockrum via MCOH-EH
Sent: Wednesday, March 26, 2025 2:55 PM
To: MCOH-EH <mcoh-eh@mylist.net>
Cc: David S. Cockrum <David.S.Cockrum@hitchcock.org>
Subject: [MCOH-EH] Urine Drug Screen Tested Drugs

 

This is sort of a cross-over MRO question (but I’ve somehow disconnected from the MRO listserv) but is also related to my role as Medical Director of Employee Health and Wellness. We have recently discovered that some of our remote employees

This is sort of a cross-over MRO question (but I’ve somehow disconnected from the MRO listserv) but is also related to my role as Medical Director of Employee Health and Wellness.

 

We have recently discovered that some of our remote employees live in states that require employers to specifically name the drugs that are being tested during pre-employment. Local pre-employment evals are tested with a standard 12-panel which we mimic as close as we can through the collection site/commercial lab nearest the candidate, but sometimes these are 10 panels, 9 panels, or whatever.

 

I am being asked to come up with a list of “must test” drugs that we can have in policy. Including the SAMHSA 5 (federal 5, DOT 5, or whatever you want to call them) is definitely a starting point. Was wondering if anyone has a reference for this, or experience. It seems the most common drug not included in panels is buprenorphine – I wouldn’t mind not including it in our list, but I need to understand risk of abuse to ensure we don’t overlook potential for patient harm, etc.

 

Appreciate any thoughts, and if anyone has the MRO list info, please share that with me (david.s.cockrum@hitchcock.org) so I can post there as well.

 

Thanks,

 

David

 

David S. Cockrum, MD, MPH
He/Him/His

Medical Director & Section Chief

Occupational & Environmental Medicine
Department of Medicine

Tel (603) 653-3881 | Fax (603) 650-0930
Dartmouth-Health.org

 

Dartmouth Hitchcock Medical Center 

 



IMPORTANT NOTICE REGARDING THIS ELECTRONIC MESSAGE:

This message is intended for the use of the person to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the intended recipient, your use of this message for any purpose is strictly prohibited. If you have received this communication in error, please delete the message and notify the sender so that we may correct our records.


Reminder: This e-mail and any attachments are subject to the current HHC email retention policies. Please save or store appropriately in accordance with policy.